Adinazolam

Adinazolam
Clinical data
Trade namesDeracyn
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • BR: Class B1 (Psychoactive drugs)
  • CA: Schedule IV
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class C
  • US: Unscheduled (Not FDA approved)
  • UN: Unscheduled
Pharmacokinetic data
MetabolismHepatic
MetabolitesN-desmethyladinazolam

N, N-didesmethyladinazolam estazolam

alpha-hydroxy-alprazolam
Elimination half-life< 3 hours
ExcretionRenal
Identifiers
  • 1-(8-Chloro-6-phenyl-4H-[1,2,4]triazolo[4,5-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H18ClN5
Molar mass351.84 g·mol−1
3D model (JSmol)
Melting point171–172.5 °C (339.8–342.5 °F)
Solubility in waterLogP: 4.16

Soluble in dichloromethane and methanol

Salt (mesylate) soluble in water mg/mL (20 °C)
  • Clc3cc2\C(=N/Cc1nnc(n1c2cc3)CN(C)C)c4ccccc4
  • InChI=1S/C19H18ClN5/c1-24(2)12-18-23-22-17-11-21-19(13-6-4-3-5-7-13)15-10-14(20)8-9-16(15)25(17)18/h3-10H,11-12H2,1-2H3 Y
  • Key:GJSLOMWRLALDCT-UHFFFAOYSA-N Y
  (verify)

Adinazolam (marketed under the brand name Deracyn) is a tranquilizer of the triazolobenzodiazepine (TBZD) class, which are benzodiazepines (BZDs) fused with a triazole ring. It possesses anxiolytic, anticonvulsant, sedative, and antidepressant properties. Adinazolam was developed by Jackson B. Hester, who was seeking to enhance the antidepressant properties of alprazolam, which he also developed. Adinazolam was never FDA approved and never made available to the public market; however, it has been sold as a designer drug.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.